CSL Stock

CSL EBIT

The EBIT of CSL (CSL.AX) as of Jul 7, 2026 is 4.1 TT USD.In the previous year, EBIT was 3.81 TT USD — a change of 7.66% (higher).

EBIT

4.1 TTUSD

YoY

7.66%

Last updated:

In 2026, CSL's EBIT was 4.1 TT USD, a 7.66% increase from the 3.81 TT USD EBIT recorded in the previous year.

The CSL EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (B USD)
Date
EBIT (B USD)
Jan 1, 2006
0.16 base
Jan 1, 2007
0.64 base
Jan 1, 2008
0.9 base
Jan 1, 2009
1.05 base
Jan 1, 2010
1.23 base
Jan 1, 2011
1.2 base
Jan 1, 2012
1.3 base
Jan 1, 2013
1.52 base
Jan 1, 2014
1.66 base
Jan 1, 2015
1.77 base
Jan 1, 2016
1.44 base
Jan 1, 2017
1.77 base
Jan 1, 2018
2.38 base
Jan 1, 2019
2.5 base
Jan 1, 2020
2.72 base
YEAREBIT (B USD)
2031 est -
2030 est 5.94
2029 est 5.7
2028 est 5.44
2027 est 5.12
2026 est 4.86
2025 4.1
2024 3.81
2023 3.25
2022 2.93
2021 3.13
2020 2.72
2019 2.5
2018 2.38
2017 1.77
2016 1.44
2015 1.77
2014 1.66
2013 1.52
2012 1.3
2011 1.2
2010 1.23
2009 1.05
2008 0.9
2007 0.64
2006 0.16
Access this data via the Eulerpool API

CSL Revenue

CSL Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2006
2.17 B USD
158.4 M USD
87.7 M USD
Jan 1, 2007
2.6 B USD
643 M USD
423.3 M USD
Jan 1, 2008
3.4 B USD
896.3 M USD
627.9 M USD
Jan 1, 2009
3.69 B USD
1.05 B USD
842.2 M USD
Jan 1, 2010
4.06 B USD
1.23 B USD
926.7 M USD
Jan 1, 2011
4.26 B USD
1.2 B USD
936.5 M USD
Jan 1, 2012
4.77 B USD
1.3 B USD
1.01 B USD
Jan 1, 2013
5.13 B USD
1.52 B USD
1.22 B USD
Jan 1, 2014
5.52 B USD
1.66 B USD
1.31 B USD
Jan 1, 2015
5.63 B USD
1.77 B USD
1.38 B USD
Jan 1, 2016
6.12 B USD
1.44 B USD
1.24 B USD
Jan 1, 2017
6.92 B USD
1.77 B USD
1.34 B USD
Jan 1, 2018
7.92 B USD
2.38 B USD
1.73 B USD
Jan 1, 2019
8.54 B USD
2.5 B USD
1.92 B USD
Jan 1, 2020
9.15 B USD
2.72 B USD
2.1 B USD

CSL Margins

CSL stock margins

The CSL margin analysis displays the gross margin, EBIT margin, as well as the profit margin of CSL. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for CSL.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2006
41.39 %
7.3 %
4.04 %
Jan 1, 2007
47.56 %
24.73 %
16.28 %
Jan 1, 2008
49.17 %
26.4 %
18.49 %
Jan 1, 2009
52.21 %
28.51 %
22.82 %
Jan 1, 2010
52.59 %
30.32 %
22.84 %
Jan 1, 2011
50.74 %
28.27 %
21.97 %
Jan 1, 2012
50.39 %
27.16 %
21.25 %
Jan 1, 2013
53.38 %
29.54 %
23.71 %
Jan 1, 2014
52.86 %
30 %
23.66 %
Jan 1, 2015
53.7 %
31.51 %
24.5 %
Jan 1, 2016
50.08 %
23.51 %
20.32 %
Jan 1, 2017
51.94 %
25.55 %
19.32 %
Jan 1, 2018
55.38 %
30.07 %
21.84 %
Jan 1, 2019
55.95 %
29.33 %
22.47 %
Jan 1, 2020
57.11 %
29.69 %
22.98 %

CSL Stock analysis

What does CSL do? CSL Ltd is a global leading company in the field of biological medicine, manufacturing a wide range of products used in the therapy of diseases. The company is based in Melbourne, Australia, and is one of the largest biotech companies in the country. CSL was founded in 1916 by Australian researcher Frank Macfarlane Burnet. Originally named Commonwealth Serum Laboratories, the company focused on the research and production of vaccines. CSL was then privatized in 1994 and changed its name to CSL Ltd. CSL's business model is based on the production of protein products and plasma derivatives used in immunotherapy, hematology, and transplantation medicine. The company specializes in the production and marketing of products in three main areas: plasma products, vaccines, and animal health. CSL's plasma division includes a variety of products, including intravenous immunoglobulins (IVIG), platelets, and alpha-1 antitrypsin. The company operates a number of plasma centers in the US and Europe to collect raw materials for these products. In the vaccine sector, CSL is primarily involved in the manufacture of influenza vaccines and also offers a range of other vaccines, including vaccines against snake bites and encephalitis. In the field of animal health, CSL produces animal vaccines to prevent viral infections in livestock such as pigs, poultry, and cattle. CSL is committed to research and development to develop new products and improve existing ones. The company has a long history in the research and development of vaccines and immunotherapies and has established a strong presence in this field. The company employs over 27,000 people in 35 countries worldwide and operates production facilities in Australia, the US, Europe, and Asia. CSL's headquarters are located in Parkville, a suburb of Melbourne, Australia. CSL has an impressive track record in terms of growth and profitability and is a stable market leader in its field. The company has achieved solid growth rates in recent years and generated a revenue of $8.5 billion in 2019. CSL is a key player in the global healthcare industry and has established a reputation as a reliable supplier of medical products and services. The company is committed to developing innovative solutions to advance medical progress and make a positive contribution to human health. CSL is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing CSL's EBIT

CSL's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of CSL's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

CSL's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in CSL’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about CSL stock

EBIT of CSL amounted to 3.81 TT USD 4.1 TT

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — CSL

All Key Metrics — CSL